Do You Know JAK? Evolving Role of JAK Inhibitors in RA

The goal of this activity is to increase awareness of clinical trial data for Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA) and incorporating these agents into treatment paradigms.

Target Audience

This activity is intended for rheumatologists, primary care physicians, orthopedists & orthopedic surgeons.

Learning Objectives

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Role of JAK/ signal transducer and activator of transcription (STAT) pathway in the pathophysiology of RA
    • Latest evidence base on novel JAK inhibitors in RA 
  • Have greater competence related to
    • Identifying RA patients who are candidates for JAK inhibitor therapy
  • Demonstrate greater confidence in their ability to
    • Evaluate the role of JAK inhibitors in patients with moderate-to-severe RA

Additional Information

Partner: 
Medscape
Course summary
Available credit: 
  • 0.50 MOC
  • 0.50 AMA PRA Category 1 Credit™
Course opens: 
05/08/2020
Course expires: 
05/08/2021
Rating: 
0

Moderator

Roy Fleischmann, MD

Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Disclosure: Roy Fleischmann, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Gilead; Lilly; Pfizer
Served as a speaker or a member of a speakers bureau for: AbbVie
Received grants for clinical research from: AbbVie; Gilead; Lilly; Pfizer

Panelists

Stanley Cohen, MD

Clinical Professor of Medicine
University of Texas Southwestern Medical Center
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Disclosure: Stanley Cohen, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Gilead; Lilly; Pfizer
Received grants for clinical research from: AbbVie; Gilead; Lilly; Pfizer

Allan Gibofsky, MD, JD

Professor of Medicine
Healthcare Policy and Research
Weill Cornell Medicine
Attending Rheumatologist
Co-Director
Clinic for Inflammatory Arthritis and Biologic Therapy
Hospital for Special Surgery
New York, New York

Disclosure: Allan Gibofsky, MD, JD has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie; Gilead; Lilly; Novartis; Pfizer; Samumed
Served as a speaker or a member of a speakers bureau for: AbbVie; Lilly; Novartis; Pfizer
Owns stock, stock options, or bonds from: AbbVie; Amgen; Bristol Myers Squibb; Johnson and Johnson; Pfizer

Editor

Karen Badal, MD, MPH

Senior Medical Education Director, Medscape, LLC

Disclosure: Karen Badal, MD, MPH, has disclosed the following relevant financial relationships:
Owns stock, stock options, or bonds from: Kallyope Inc.

CME Reviewer

Hazel Dennison, DNP, RN, FNP, CPHQ, CNE

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

image

image

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Available Credit

  • 0.50 MOC
  • 0.50 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through Medscape. To take this course you will be redirected to Medscape's website. You must have an account with Medscape in order to complete this activity. 

MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!